论文部分内容阅读
阿斯利康公司宣布更新其MEK 1/2抑制剂司美替尼(selumetinib)伍用多西他赛治疗KRAS突变阳性、局部晚期或转移性非小细胞肺癌的Ⅲ期临床SELECT-1试验资料。该试验是国际性、随机、双盲、安慰剂对照研究,有200个中心参与,入选510名非小细胞肺癌患者,口服该药75 mg,2次/日,伍用多西他赛,静脉注射75 mg/m~2,
AstraZeneca Announces Phase III Clinical SELECT-1 Trial Update of its MEK 1/2 Inhibitor Selumetinib versus Docetaxel in the Treatment of KRAS Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. This trial is an international, randomized, double-blind, placebo-controlled study of 200 centers enrolled in 510 patients with non-small cell lung cancer who received oral administration of 75 mg twice daily, docetaxel, Injection 75 mg / m ~ 2,